ISPOR Europe is one of the key milestones for anyone working at the intersection of evidence, value, and access. In Glasgow, from 9-12 November 2025, ProductLife Group participated together with affiliates Intexo Società Benefit, Outcomes'10 and Nextep Health with a clear message: turn data and insights into decisions that matter for HTA, pricing & reimbursement and Market & Patient Access across European health systems.
Highlights from the conference
Conversations on site revolved around four pillars that match payer and decision-maker priorities:
- Access and value: building credible value narratives, rooted in clinical and real-world outcomes, to support negotiation and reimbursement
- HEOR and RWE: robust designs and cost-effectiveness/budget-impact models that withstand methodological and regulatory scrutiny
- HTA and health policy: understanding how countries interpret cost-effectiveness thresholds, evidence requirements, and performance-based agreements
- Patient-centred programs: embedding patient priorities, preferences and quality of life so value translates into tangible results for people
Posters and scientific contributions
The PLG team contributed to the event presenting
11 posters
, offering comparative and practical perspectives on topics that determine access today:
- Resilient Pharmaceutical Supply Chains in Times of Crisis - A comparative analysis of Australia, France, Italy, Spain and the UK: how medicine supply chains respond to shocks and which regulatory/organizational levers strengthen resilience
- Relationship Between Cost-Effectiveness Threshold and Drug Reimbursement in Spain, Italy, and France - Links between cost-effectiveness thresholds, HTA criteria and reimbursement decisions
- Joint Clinical Assessments and evaluations with non-RCT evidence - Methodological and regulatory implications in the evolving European context
- Psoriasis: from a review of patient decision aids to understanding drivers of patient choice and measuring quality of life with DLQI-R in older populations
- Cost of Care in relapsing-remitting multiple sclerosis (Spanish NHS perspective) and healthcare/economic burden of IV/SC immunoglobulins across three autoimmune neuromuscular diseases (bicentric Spanish experience)
- Country-specific economic evaluations, including:
- Cost-effectiveness of difelikefalin for CKD-associated pruritus in haemodialysis (Italy)
- Nemolizumab for moderate-to-severe prurigonodularis (Italy)
- Evolution of pharmaceutical pricing and reimbursement agreements in Spain over the last decade, moving toward outcomes-based approaches
A common thread runs through these works: giving
decision-makers
operational tools. Not just results but
replicable methods
, transparent assumptions, tested sensitivities and clear guidance on turning evidence into
informed negotiations
,
country-aligned dossiers
and
sustainable adoption
.
From methodology to execution
Discussions at our booth reinforced several cross-cutting needs:
- Link evidence and access early: integrate HEOR/RWE inputs during development to avoid late rework that delays time-to-access
- Localize without losing coherence: a common framework for multiple countries, with targeted adaptations to requirements, available data and stakeholder priorities
- Choose the right outcomes: clinical endpoints, PROs, and quality-of-life measures that speak the language of payers and clinicians
- Governance and measurability: processes, metrics, and versioning that ensure traceability and speed across submission, negotiation, and follow-up
How PLG supports teams
With an integrated network of capabilities, PLG partners with biopharma and medtech companies along the full journey
from evidence to access
:
- Market & Patient Access: early asset positioning, pathway mapping, stakeholder engagement
- Pricing & Reimbursement / HTA: value dossiers, negotiation strategies and responses aligned to national requirements
- HEOR: rigorous, defensible cost-effectiveness and budget-impact models
- RWD/RWE: study design, evidence generation, and translation of insights into payer-relevant decisions
- Patient-centred Research: tools, preferences, and quality of life to connect science, experience, and value
- Market Intelligence: competitive, epidemiology, and policy monitoring to inform country prioritization and timing
Our approach is
pragmatic and repeatable
: shared methodological structures tailored to local contexts, transparent assumptions, and a constant focus on
credibility
and
sustainability
of proposed solutions
Looking ahead
Pressure on
sustainability, value-for-money, and measurable outcomes
will keep increasing. That's why we invest in models and skills that help teams
prepare early
, aligning study pipelines with HTA and negotiation needs, and turning evidence into
access
and
impact
for patients.
ISPOR 2025 marked an important step in this direction: a place to shift the dialogue from "what data?" to "what decisions can we take, now?"
If you're interested or would like to explore further, contact us
Contact us